Unusual Machines Grants CEO Performance-Based Warrants and Executive Stock Options

CEO Compensation Restructuring Centered on Performance Milestones

The Compensation Committee of Unusual Machines approved a material shift in how the company compensates its chief executive officer on July 24, 2026. Dr. Allan Evans, the Company's Chief Executive Officer, received approval for a warrant grant to purchase 5 million shares of common stock. This arrangement represents a performance-focused compensation model in which Dr. Evans has agreed to waive all cash compensation from the Company effective January 1, 2027. The warrant grant is structured to reward significant share price appreciation, with each of the five tranches vesting only when the company's stock achieves increasingly ambitious price targets over specified measurement periods.

The warrants carry an exercise price of $25.00 per share and will expire on July 24, 2031. This five-year term provides Dr. Evans with a defined window to exercise the warrants should the vesting conditions be satisfied. The structure effectively aligns the CEO's financial interests with shareholder value creation, as the executive will have no guaranteed cash income following the end of 2026 and will instead depend on warrant vesting tied to stock performance. This type of arrangement is sometimes adopted by companies seeking to preserve cash while incentivizing management to achieve substantial growth objectives.

Warrant Vesting Structure and Share Price Targets

The warrant grant features a five-tranche vesting schedule directly tied to the company's stock performance. Each of the five tranches consists of 1 million warrants and will vest when the company's common stock reaches specific price targets: $25.00, $40.00, $60.00, $80.00, and $100.00 per share, respectively. The disclosure states that each price target will be deemed achieved when the average closing price of the company's common stock over any 20-consecutive trading day period equals or exceeds the applicable target price. This measurement methodology means the company's stock must sustain elevated levels for a full month of trading to trigger vesting, rather than requiring only a momentary price spike.

The progressive nature of the vesting schedule creates escalating incentives. The first tranche vests at the $25.00 target, which may be viewed as a near-term objective, while subsequent tranches require increasingly substantial share price appreciation. The highest tranche requires the stock to achieve $100.00 per share, representing a significant long-term value creation goal. This structure ensures that Dr. Evans benefits materially only if the company delivers sustained improvements in shareholder value. The warrant grant is subject to shareholder approval, meaning the arrangement requires ratification by the company's stockholders before becoming fully effective.

Additional Executive Stock Option Grants and Vesting Terms

In addition to the CEO warrant grant, the Compensation Committee approved stock option grants to three other key executives on the same date. President Andrew Camden received approval for 525,000 stock options, Chief Financial Officer Brian Hoff received 375,000 options, and Chief Revenue Officer Stacy Wright received 375,000 options. All stock options are exercisable at $19.36 per share and represent five-year grants. Unlike the CEO's performance-based warrants, these options include more traditional vesting mechanics tied to continued service rather than stock price targets.

The stock options will vest in 12 equal quarterly installments over a three-year period from the grant date, contingent on each officer's continued employment with the company through the applicable vesting date. This time-based vesting approach is designed to retain executives by spreading benefits across a multi-year period and creating financial incentives for ongoing service. The three-year vesting window for quarterly tranches is a standard practice in corporate executive compensation, as it encourages workforce stability while gradually increasing the executive's ownership stake in the company. The exercise price of $19.36 per share was established on the grant date and will remain fixed for the five-year term of the options.

CEO Cash Compensation Waiver and Long-Term Incentive Focus

A distinctive feature of the CEO warrant arrangement is Dr. Evans's agreement to waive all cash compensation from the Company following December 31, 2026. This commitment means that beginning January 1, 2027, the CEO will receive no salary, bonus, or other cash-based compensation from Unusual Machines. The filing indicates this waiver was made in consideration for the warrant grant, suggesting the two elements were negotiated as an integrated package. This structure effectively converts the CEO's total compensation from a cash-plus-equity model to a purely equity-based model dependent on warrant vesting conditions.

The elimination of cash compensation creates a direct financial alignment between Dr. Evans's personal interests and shareholder outcomes. Without guaranteed cash income, the CEO's ability to profit from his position depends entirely on the company's ability to achieve the stock price milestones embedded in the warrant vesting schedule. This arrangement may be intended to signal management confidence in the company's growth prospects and to demonstrate to investors that leadership is willing to bet its own financial future on the company's execution. However, investors may also consider whether the elimination of cash compensation could affect the company's ability to retain or attract other key talent or whether it reflects cost pressures at the organization.

Shareholder Approval Requirement for Warrant Grant

The disclosure explicitly states that the warrant grant is subject to shareholder approval, meaning the arrangement cannot become fully operative without a vote by the company's stockholders. This approval requirement is a standard governance control for material executive compensation arrangements and provides shareholders with a formal opportunity to ratify or reject the proposed terms. The timing of when shareholder approval will be sought is not specified in the filing. Investors monitoring this situation should watch for a proxy statement or other shareholder notice announcing the upcoming vote and providing additional context or board recommendations regarding the proposed warrant grant.

The shareholder approval requirement adds an important element of uncertainty regarding whether the arrangement will ultimately be implemented as proposed. While the Compensation Committee has already approved the terms, final implementation is contingent on stockholder support. The specific vote threshold required (simple majority, supermajority, or other standard) is not specified in the filing. Shareholders will have the opportunity to evaluate the arrangement in detail and determine whether they believe the performance-based warrant structure adequately aligns executive and shareholder interests or whether alternative compensation approaches would be preferable.

Unusual Machines' Emerging Growth Company Status

The disclosure indicates that Unusual Machines qualifies as an emerging growth company as defined under applicable securities regulations. The company has not elected to use the extended transition period for complying with new or revised financial accounting standards. This status affects certain regulatory and reporting obligations applicable to the company. Emerging growth company status typically provides relief from certain compliance requirements while the company remains below applicable thresholds for revenue or other metrics, though the company has chosen to adopt new accounting standards on a standard timeline rather than using any available extended transition periods.

The company's headquarters are located in Orlando, Florida, and its common stock trades on NYSE American under the ticker symbol UMAC. The company was incorporated in Nevada and maintains a primary executive office address at 5728 Major Boulevard, Suite 250, Orlando, Florida 32819. These details provide context regarding the company's domicile, exchange listing, and operational location but do not affect the substance of the compensation arrangement disclosed in this report.

Executive Compensation Context and Market Signals

The timing and structure of this compensation announcement may signal several messages to the investment community. The fact that the company is restructuring the CEO's compensation to be entirely warrant-based and cash-free following year-end 2026 could indicate management's confidence in the company's ability to achieve significant share price appreciation over the coming years. Alternatively, it could reflect cost management considerations or a deliberate strategy to preserve cash for operational needs. The disclosure does not provide explicit guidance regarding management's expectations for future share price performance or the timeframe in which management anticipates the vesting targets might be achieved.

The aggressive price targets embedded in the warrant vesting schedule—particularly the $100.00 per share maximum tranche—represent substantial appreciation from current or recent trading levels and suggest management views significant growth as achievable. However, investors should note that warrant vesting is contingent on these targets being met, and there is no assurance that they will be realized. The structure incentivizes Dr. Evans to pursue strategic initiatives and execution that could drive sustained share price appreciation, potentially benefiting other shareholders alongside the CEO.

Disclosure Date and Filing Details

The compensation arrangement was formally approved on July 24, 2026, and the company filed this current report on July 28, 2026, in accordance with Securities Exchange Act requirements. The filing was executed and signed by Chief Financial Officer Brian Hoff on behalf of the company. The report was filed under Item 5.02 of Form 8-K, which covers departures and appointments of directors and officers as well as compensatory arrangements of certain officers. This filing requirement ensures that material changes to executive compensation terms are disclosed promptly to the market and to investors who rely on current information for investment decision-making.

The company's Commission File Number is 001-41961, and its IRS Employer Identification Number is 66-0927642. These identifiers facilitate cross-referencing with other regulatory filings and regulatory documents. The disclosure of this compensation arrangement is part of the company's ongoing obligations to provide transparent and timely information regarding material corporate events and executive compensation decisions. Investors who hold or are considering investment in Unusual Machines' securities may use this information as one factor in evaluating the company's management approach and capital allocation priorities.